Type1diabetes Clinical Trial
Official title:
Using a Virtual Care Platform to Deliver Peer-led Mental Health Support to Rural and Remote Communities in BC: A Randomized Wait-list Controlled Trial of the REACHOUT Intervention
The purpose of this study is to investigate the effectiveness of participation in a 6-month peer-led mental health support program, delivered via a mobile app (REACHOUT), to adults with type 1 diabetes compared to a wait-list control condition. Participants will connect with a Peer-Supporter (an adult with type 1 diabetes trained in providing mental health support), and have access to the app features including a 24/7 chat room and face-to-face support delivered via virtual happy hours.
Status | Not yet recruiting |
Enrollment | 220 |
Est. completion date | May 31, 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - have type 1 diabetes (T1D) - be 19 years or older - reside in one of the targeted health authorities in British Columbia (Fraser Health, Island Health, Northern Health, and Interior Health Authorities) - be English proficient - have an average diabetes distress (DD) Subscale Score = 2 - have access to the internet and/or a smartphone. Exclusion Criteria: - Participants with a pre-existing mental health condition, multiple co-morbidities, substance use challenges, and or any other condition that may prevent meaningful participation may not participate in this study. |
Country | Name | City | State |
---|---|---|---|
Canada | University of British Columbia | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Brain Canada, Juvenile Diabetes Research Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Diabetes Distress | Diabetes Distress will be measured by the Type 1 Diabetes Distress Scale (T1D-DDS). This scale contains 28 items that people with type 1 diabetes may find distressing. Participants rate each item on a scale from 1 indicating Not a Problem to 6 indicating a Very Serious Problem. There are seven subscales including powerlessness, management distress, hypoglycemia distress, negative social distress, eating distress, physician distress, and family/friends distress. Overall and subscale scores are calculated by taking the mean of items in the overall or subscale. A higher score indicates higher diabetes distress. | 0, 6 month(s) | |
Secondary | Change in Perceived social support | Perceived Social Support will be assessed using the Diabetes-Specific Perceived Social Support Scale. This scale presents a list of ways that people give and receive support, and asks participants to indicate the degree to which each statement is true for them. Participants may rate each item from 0 indicating No Support to 4 indicating a Great Deal of Support. A higher score indicates higher perceived social support. | 0, 6 month(s) | |
Secondary | Change in Depressive Symptom Severity | Depressive Symptom Severity will be assessed using the Personal Health Questionnaire 8 (PHQ-8). This questionnaire asks participants how bothered they have been by various problems over the past two weeks. Participants rate each item from 0 indicating Not At All to 3 indicating Nearly Every Day. A total score is calculated by adding up the ratings for each item. A higher score indicates higher depressive symptom severity. | 0, 6 month(s) | |
Secondary | Change in Resilience | Resilience will be assessed by the Diabetes Strengths and Resilience (DSTAR) Measure for Emerging Adults. The scale presents a list of items that people with diabetes sometimes think. Items are scored on a 5-point Likert scale from never "1" to almost always "5". A total score is calculated by taking a sum of all items. A higher score indicates higher resilience. | 0, 6 month(s) | |
Secondary | Change in Diabetes-Specific Quality of Life | Diabetes-Specific Quality of Life will be measured by the Type 1 Diabetes Activities and Living (T1DAL). The survey questions ask participants what their life is like with diabetes including what is going well for them or what they could use more help with. There are different variations of the questionnaire for each of the following age cohorts: 18 - 25 years old, 26 - 45 years old, 46 - 60 years old, > 60 years old. Participants answer each item with the following options: (1) No, not at all true; (2) No, not very true; (3) Sometimes true, sometimes not true; (4) Yes, a little true; (5) Yes, very true. | 0, 6 month(s) | |
Secondary | Change in Health-Related Quality of Life | Health-Related Quality of Life will be measured by the EuroQol-5D-5 level version (EQ-5D-5L), which asks questions regarding general health. Participants are asked to choose from a variety of statements for each question which best describes their health. | 0, 3, 6 month(s) | |
Secondary | Change in Quality Adjusted Life year (QALY) | Change Quality Adjusted Life Year (QALY) will be estimated using the Visual Analogue Scale (VAS) of the EuroQol-5D-5 level version (EQ-5D-5L). The VAS asks participants to self-rate their health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. | 0, 3, 6 month(s) | |
Secondary | Change in Health Related Costs | Change in Health Related Costs will be measured by the Health Resource Utilization Questionnaire (HRU). This questionnaire asks a series of questions regarding health resource utilization and costs patients may have incurred. | 0, 3, 6 month(s) | |
Secondary | Change in Hemoglobin A1c | Hemoglobin A1c (HbA1c) will be measure via blood collection | 0, 6 month(s) | |
Secondary | Change in % Time in Range | In British Columbia, the continuous glucose monitor (CGM) brand that is covered by provincial health care is the Dexcom G6. As such, we will request to collect % time in range data from all participants who are using this CGM. Because the G6 CGM is pre-calibrated by the factory, participants do not need to self-calibrate. CGM units will be retrieved by the research team every two weeks using Dexcom Clarity software (Dexcom, San Diego, CA). | Up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03886974 -
Transition to Adult Care in Type 1 Diabetes
|
||
Completed |
NCT05620251 -
Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
|
||
Completed |
NCT03623113 -
The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05078658 -
Low-carbohydrate Diet in Children With Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06018324 -
CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
|
||
Withdrawn |
NCT03736083 -
Introducing CGM at Type 1 Diabetes Diagnosis
|
N/A | |
Completed |
NCT03177096 -
Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06418269 -
The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes
|
N/A | |
Completed |
NCT04172077 -
Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
|
||
Recruiting |
NCT04950634 -
Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
|
||
Completed |
NCT04450745 -
Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients
|
N/A | |
Completed |
NCT03165786 -
A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
|
N/A | |
Terminated |
NCT04028960 -
IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase
|
Phase 2 | |
Recruiting |
NCT05324488 -
Diabetes Registry Graz for Biomarker Research
|
||
Completed |
NCT02984709 -
Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes
|
N/A | |
Completed |
NCT02984514 -
Brown Adipose Tissue in Type 1 Diabetes
|
N/A | |
Recruiting |
NCT06372392 -
Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps
|
N/A | |
Recruiting |
NCT03311516 -
New Insulin Therapy by Multiwave Bolus
|
N/A | |
Recruiting |
NCT05973799 -
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
|
N/A | |
Completed |
NCT03711656 -
Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques
|
N/A |